ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TYRA vs PCRX // RSI-14 & 200D SMA MOMENTUM

Tyra Biosciences Inc. (NASDAQ) VS. Pacira BioSciences Inc. (NASDAQ) • 15-METRIC TALLY: TYRA 1 — PCRX 4
▲ RSI-14 & 200D SMA MOMENTUM LEADER: PCRX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TYRA VS. PCRX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TYRA PCRX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 79.40% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 1.70% -36.70 PCRX /roic <GO>
EV/EBITDA & P/E Valuation — 51.6x — TIE /valuation <GO>
Free Cash Flow Yield -6.45% 9.42% -15.87 PCRX /fcf-yield <GO>
Operating Margin — 2.60% — TIE /operating-margins <GO>
Net Profit Margin — 1.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 3.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 2.33 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 8/9 -6.00 PCRX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 49.0 83.2 -34.25 PCRX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.48B $1.45B $26.3M TYRA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TYRA REV PCRX REV TYRA GROSS % PCRX GROSS % TYRA FCF PCRX FCF
FY 2025 $0 $726.4M — 79.4% -$95.3M $136.7M
FY 2024 $0 $701.0M — 75.7% -$70.4M $178.8M
FY 2023 $0 $675.0M — — -$50.1M $154.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TYRA // BETA —
PCRX // BETA —